Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

NewAmsterdam Pharma Grants 106,600 Share Options to Six New Hires

By Public Technologies
  • NewAmsterdam Pharma granted share options covering 106,600 ordinary shares to six non-executive new hires under its 2024 Inducement Plan.
  • Restricted stock units covering 28,295 ordinary shares went to six non-executive new hires. Both grants were dated November 2, 2026.
  • Share options vest over four years: 25% on the first vesting anniversary, with the balance in 36 equal monthly installments.
  • Restricted stock units vest over three years, with one-third vesting on each annual anniversary of the vesting commencement date.
  • Vesting of both awards depends on continued service.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061601PRIMZONEFULLFEED9871874) on November 06, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.